Abstract
A prospective study of antipsychotic drug treatment showed no difference in response between schizophrenic in-patients with or without a familial predisposition to the illness (N = 53). All patients received at least 600 mg chlorpromazine equivalents antipsychotic medication for 6 weeks. Ventricle brain ratios, ratings of cortical sulcal widening and a history of obstetric complications also failed to account for the variability, but early age of onset was associated with unsatisfactory response.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Antipsychotic Agents / therapeutic use*
-
Brain Damage, Chronic / complications*
-
Cerebral Ventricles / pathology*
-
Chlorpromazine / therapeutic use
-
Female
-
Humans
-
Male
-
Neurocognitive Disorders / drug therapy*
-
Neurocognitive Disorders / pathology
-
Prognosis
-
Risk Factors
-
Schizophrenia / drug therapy*
-
Schizophrenia / genetics
-
Schizophrenia / pathology
-
Schizophrenic Psychology*
-
Tomography, X-Ray Computed
Substances
-
Antipsychotic Agents
-
Chlorpromazine